PBE vs. ARKG
Compare and contrast key facts about Invesco Dynamic Biotechnology & Genome ETF (PBE) and ARK Genomic Revolution Multi-Sector ETF (ARKG).
PBE and ARKG are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. PBE is a passively managed fund by Invesco that tracks the performance of the Dynamic Biotech & Genome Intellidex Index (AMEX). It was launched on Jun 23, 2005. ARKG is an actively managed fund by ARK Investment Management. It was launched on Oct 31, 2014.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: PBE or ARKG.
Correlation
The correlation between PBE and ARKG is 0.79, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Performance
PBE vs. ARKG - Performance Comparison
Key characteristics
PBE:
-0.35
ARKG:
-0.70
PBE:
-0.36
ARKG:
-0.85
PBE:
0.96
ARKG:
0.91
PBE:
-0.22
ARKG:
-0.36
PBE:
-1.32
ARKG:
-2.29
PBE:
5.03%
ARKG:
13.08%
PBE:
18.83%
ARKG:
42.95%
PBE:
-45.69%
ARKG:
-83.00%
PBE:
-29.46%
ARKG:
-83.00%
Returns By Period
In the year-to-date period, PBE achieves a -11.20% return, which is significantly higher than ARKG's -19.30% return. Over the past 10 years, PBE has outperformed ARKG with an annualized return of 0.77%, while ARKG has yielded a comparatively lower -1.10% annualized return.
PBE
-11.20%
-9.85%
-15.01%
-5.56%
5.54%
0.77%
ARKG
-19.30%
-20.77%
-23.57%
-28.76%
-8.36%
-1.10%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
PBE vs. ARKG - Expense Ratio Comparison
PBE has a 0.59% expense ratio, which is lower than ARKG's 0.75% expense ratio.
Risk-Adjusted Performance
PBE vs. ARKG — Risk-Adjusted Performance Rank
PBE
ARKG
PBE vs. ARKG - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Invesco Dynamic Biotechnology & Genome ETF (PBE) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
PBE vs. ARKG - Dividend Comparison
PBE's dividend yield for the trailing twelve months is around 0.07%, while ARKG has not paid dividends to shareholders.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
PBE Invesco Dynamic Biotechnology & Genome ETF | 0.07% | 0.05% | 0.02% | 0.00% | 0.00% | 0.04% | 0.00% | 0.00% | 0.57% | 0.38% | 1.12% | 0.55% |
ARKG ARK Genomic Revolution Multi-Sector ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.62% | 0.85% | 3.14% | 1.94% | 1.34% | 0.00% | 0.00% | 0.00% |
Drawdowns
PBE vs. ARKG - Drawdown Comparison
The maximum PBE drawdown since its inception was -45.69%, smaller than the maximum ARKG drawdown of -83.00%. Use the drawdown chart below to compare losses from any high point for PBE and ARKG. For additional features, visit the drawdowns tool.
Volatility
PBE vs. ARKG - Volatility Comparison
The current volatility for Invesco Dynamic Biotechnology & Genome ETF (PBE) is 7.14%, while ARK Genomic Revolution Multi-Sector ETF (ARKG) has a volatility of 14.81%. This indicates that PBE experiences smaller price fluctuations and is considered to be less risky than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.